Page 137 - 《中国药房》2024年4期

in patients with cancer[J]. Nat Rev Clin Oncol，2022，19 [23] BRUIX J，QIN S K，MERLE P，et al. Regorafenib for pa‐
（11）：681-697. tients with hepatocellular carcinoma who progressed on
[11] LINDNER A U，RESLER A J，CARBERRY S，et al. Sys‐ sorafenib treatment（RESORCE）：a randomised，double-
tems biology analysis identifies molecular determinants of blind，placebo-controlled，phase 3 trial[J]. Lancet，2017，
chemotherapy-induced diarrhoea[J]. J Mol Med，2020，98 389（10064）：56-66.
（1）：149-159. [24] ABOU-ALFA G K，MEYER T，CHENG A L，et al. Cabo‐
[12] YOKOTA T，UENO T，SOGA Y，et al. J-SUPPORT re‐ zantinib in patients with advanced and progressing hepato‐
search policy for oral mucositis associated with cancer cellular carcinoma[J]. N Engl J Med，2018，379（1）：54-63.
treatment[J]. Cancer Med，2022，11（24）：4816-4829. [25] SCHLUMBERGER M，TAHARA M，WIRTH L J，et al.
[13] KREIS W，PETRYLAK D，SAVARESE D，et al. Colitis Lenvatinib versus placebo in radioiodine-refractory thy‐
and docetaxel-based chemotherapy[J]. Lancet，2000，355 roid cancer[J]. N Engl J Med，2015，372（7）：621-630.
（9221）：2164. [26] SMITH D C，SMITH M R，SWEENEY C，et al. Cabozan‐
[14] GHIRINGHELLI F，VINCENT J，BELTJENS F，et al. tinib in patients with advanced prostate cancer：results of a
Fluorouracil，leucovorin and irinotecan associated with af‐ phase Ⅱ randomized discontinuation trial[J]. J Clin On‐
libercept can induce microscopic colitis in metastatic col，2013，31（4）：412-419.
colorectal cancer patients[J]. Invest New Drugs，2015，33 [27] KEUTGEN X M，ORNELL K J，VOGLE A，et al.
（6）：1263-1266. Sunitinib-loaded chondroitin sulfate hydrogels as a novel
[15] SORIA J C，OHE Y，VANSTEENKISTE J，et al. Osimer‐ drug-delivery mechanism for the treatment of pancreatic
tinib in untreated EGFR-mutated advanced non-small-cell neuroendocrine tumors[J]. Ann Surg Oncol，2021，28
lung cancer[J]. N Engl J Med，2018，378（2）：113-125. （13）：8532-8543.
[16] WU Y L，CHENG Y，ZHOU X D，et al. Dacomitinib ver‐ [28] CASTAGNETTI F，RAIMONDO F D，VIVO A D，et al.
sus gefitinib as first-line treatment for patients with EGFR- A population-based study of chronic myeloid leukemia pa‐
mutation-positive non-small-cell lung cancer（ARCHER tients treated with imatinib in first line[J]. Am J Hematol，
1050）：a randomised，open-label，phase 3 trial[J]. Lancet 2017，92（1）：82-87.
Oncol，2017，18（11）：1454-1466. [29] NISHIWAKI S，MAEDA M，YAMADA M，et al. Clinical
[17] GOLDBERG S B，REDMAN M W，LILENBAUM R，et efficacy of fecal occult blood test and colonoscopy for
al. Randomized trial of afatinib plus cetuximab versus afa‐ dasatinib-induced hemorrhagic colitis in CML patients[J].
tinib alone for first-line treatment of EGFR-mutant non- Blood，2017，129（1）：126-128.
small-cell lung cancer：final results from SWOG S1403 [30] JIMÉNEZ BELTRÁN V，BERMÚDEZ ALARCÓN A，
[J]. J Clin Oncol，2020，38（34）：4076-4085. CASTAÑO FERNÁNDEZ O. Dasatinib-induced colitis：
[18] VAN CUTSEM E，PEETERS M，SIENA S，et al. Open- discovering the side effects of immunotherapy[J]. Rev Esp
label phase Ⅲ trial of panitumumab plus best supportive Enferm Dig，2020，112（8）：663-664.
care compared with best supportive care alone in patients [31] ATALLAH E，SCHIFFER C A，RADICH J P，et al. As‐
with chemotherapy-refractory metastatic colorectal cancer sessment of outcomes after stopping tyrosine kinase in‐
[J]. J Clin Oncol，2007，25（13）：1658-1664. hibitors among patients with chronic myeloid leukemia：a
[19] TANIGUCHI H，YAMANAKA T，SAKAI D，et al. Effi‐ nonrandomized clinical trial[J]. JAMA Oncol，2021，7（1）：
cacy of panitumumab and cetuximab in patients with 42-50.
colorectal cancer previously treated with bevacizumab：a [32] BLAY J Y，SERRANO C，HEINRICH M C，et al.
combined analysis of individual patient data from Ripretinib in patients with advanced gastrointestinal stro‐
ASPECCT and WJOG6510G[J]. Cancers，2020，12（7）： mal tumours（INVICTUS）：a double-blind，randomised，
1715. placebo-controlled，phase 3 trial[J]. Lancet Oncol，2020，
[20] GOPAL A K，KAHL B S，DE VOS S，et al. PI3K δ inhibi‐ 21（7）：923-934.
tion by idelalisib in patients with relapsed indolent lym‐ [33] CORTES J E，GAMBACORTI-PASSERINI C，DEININGER
phoma[J]. N Engl J Med，2014，370（11）：1008-1018. M W，et al. Bosutinib versus imatinib for newly diagnosed
[21] FLINN I W，O’BRIEN S，KAHL B，et al. Duvelisib，a chronic myeloid leukemia：results from the randomized
novel oral dual inhibitor of PI3K-δ，γ，is clinically active BFORE trial[J]. J Clin Oncol，2018，36（3）：231-237.
in advanced hematologic malignancies[J]. Blood，2018， [34] FONTANELLA C，LEDERER B，NEKLJUDOVA V，et
131（8）：877-887. al. Does toxicity predict efficacy? Insight into the mecha‐
[22] ANDRÉ F，CIRUELOS E，RUBOVSZKY G，et al. Al‐ nism of action of lapatinib[J]. J Clin Oncol，2014，32（30）：
pelisib for PIK3CA-mutated，hormone receptor-positive 3458-3459.
advanced breast cancer[J]. N Engl J Med，2019，380（20）： [35] CORTÉS J，FUMOLEAU P，BIANCHI G V，et al. Pertu‐
1929-1940. zumab monotherapy after trastuzumab-based treatment

中国药房 2024年第35卷第4期 China Pharmacy 2024 Vol. 35 No. 4 · 511 ·